Sign in

    Matthew Parisi

    Research Analyst at KeyBanc Capital Markets Inc.

    Matthew Parisi is an Analyst at KeyBanc Capital Markets Inc., with a focus on equity research for the healthcare and life sciences sectors. He regularly covers companies such as Azenta Inc. and Maravai LifeSciences Holdings Inc., participating in quarterly earnings calls and providing in-depth analysis for institutional clients. Parisi began his professional finance career at KeyBanc Capital Markets and currently holds FINRA registration as a licensed securities broker, maintaining an active CRD profile since 2021. His credentials reflect a solid foundation in equity analysis, supported by relevant industry certifications and regulatory compliance.

    Matthew Parisi's questions to MARAVAI LIFESCIENCES HOLDINGS (MRVI) leadership

    Matthew Parisi's questions to MARAVAI LIFESCIENCES HOLDINGS (MRVI) leadership • Q2 2025

    Question

    Matthew Parisi of KeyBanc asked for more detail on the company's CDMO enablement strategy, specifically regarding the new CleanCap license and supply agreement with Thermo Fisher Scientific.

    Answer

    CEO Bernd Brust clarified that the agreement with Thermo Fisher is an example of their strategy to expand the use of CleanCap beyond Maravai's internal CDMO services. The goal is to have their GMP consumables, like CleanCap, used by as many CDMOs and pharmaceutical manufacturers as possible to drive broader adoption.

    Ask Fintool Equity Research AI

    Matthew Parisi's questions to Alpha Teknova (TKNO) leadership

    Matthew Parisi's questions to Alpha Teknova (TKNO) leadership • Q2 2025

    Question

    Matthew Parisi of KeyBanc Capital Markets asked for updated growth expectations for the catalog business, clarification on the drivers of the Clinical Solutions revenue rebound in Q2, and insight into revenue phasing for the second half of the year.

    Answer

    CFO Matt Lowell indicated that full-year catalog business growth is now expected to surpass the initial mid-single-digit forecast, potentially reaching high-single or low-double digits. He clarified the Q2 Clinical Solutions growth was due to general business trends, not a single large order, and projected that second-half revenue would be similar to the first, with a seasonally softer Q4.

    Ask Fintool Equity Research AI

    Matthew Parisi's questions to Alpha Teknova (TKNO) leadership • Q4 2024

    Question

    Matthew Parisi of KeyBanc Capital Markets requested an updated number of Cell and Gene Therapy customers and asked about Teknova's involvement with any commercial-stage therapies. He also asked for guidance on the expected revenue phasing for 2025.

    Answer

    President and CEO Stephen Gunstream stated that Cell and Gene Therapy customers now account for 27% of total revenue, with 23 clinical customers in this segment. He confirmed Teknova is not yet supporting any commercialized therapies, as its strategic focus on this area began in 2021. CFO Matthew Lowell provided 2025 revenue phasing guidance, expecting Q1 to be the lowest quarter, followed by sequential growth in Q2 and Q3, and a slight seasonal dip in Q4.

    Ask Fintool Equity Research AI

    Matthew Parisi's questions to Azenta (AZTA) leadership

    Matthew Parisi's questions to Azenta (AZTA) leadership • Q3 2025

    Question

    Matthew Parisi of KeyBanc Capital Markets asked if the company's 1% NIH funding headwind estimate might be revised given recent positive legislative news suggesting a potential funding increase.

    Answer

    CEO John Marotta stated that the positive news of a potential 1% NIH funding increase is consistent with their field intelligence and that they remain bullish on the outlook. He clarified that Azenta is well-positioned to support the direct research that would result from such an increase, whether through its multiomics or sample management services.

    Ask Fintool Equity Research AI